David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.
In this installment of the "Expanding Horizons" series, David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure and physician scientist at the University of Pennsylvania, explains the logistics of expanding rare disease drug access and financial considerations in clinical trials.
Fajgenbaum expresses excitement about significantly reducing the cost of trials for repurposed drugs to between $1 and $5 million, in contrast to the substantial amounts spent by drug companies on developing new drugs. According to research published in JAMA Health Forum, the National Institutes of Health spent an average of $33.8 million per FDA-approved drug between 2010 and 2019, including $13.9 million per drug for phase 1 trials, $22.2 million per drug for phase 2 trials, and $12.9 million per drug for phase 3 trials. The cost reductions by Every Cure are seen as a key element in making drug repurposing more feasible.
He also addresses insurance challenges, including the issue of setting different prices for the same drug with different indications, and discusses ongoing conversations with insurers. The goal is to pick trials strategically, where successful outcomes would economically make sense for insurers to cover the drug.
“It's all coming together right now,” Fajgenbaum said. “Frankly, we should have been doing this for a long time, but there's no time that's better than now.”
Check out part 1 and part 2 of the "Expanding Horizons" feature series. To learn more about Every Cure's work toward increasing rare disease treatments, visit www.everycure.org
Reference
Zhou EW, Jackson MJ, Ledley FD. Spending on phased clinical development of approved drugs by the US National Institutes of Health compared with industry. JAMA Health Forum. 2023;4(7):e231921. doi:10.1001/jamahealthforum.2023.1921
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More